Zheng Quan Ri Bao·2025-08-08 16:15Group 1 - Several innovative pharmaceutical companies reported impressive performance for the first half of 2025, indicating a shift towards original innovation and global registration as core growth strategies [1][3] - Ganli Pharmaceutical achieved revenue of 2.067 billion yuan, a year-on-year increase of 57.18%, and a net profit of 604 million yuan, up 101.96% [1] - BeiGene reported total revenue of 17.518 billion yuan, a 46% increase year-on-year, and a net profit of 450 million yuan, marking its first half-year profit since its A-share listing [2] Group 2 - BeiGene's product revenue growth was driven by its self-developed product, Brukinsa (Zebutinib), and sales of its licensed product, Tislelizumab, which totaled 12.527 billion yuan globally, reflecting a 56.2% increase [2] - The innovative drug industry is benefiting from supportive policies, including measures from the National Healthcare Security Administration to encourage investment in innovative drugs and the exclusion of new drugs from centralized procurement [3] - The industry is expected to enter a rapid development phase due to comprehensive policy support across the entire chain from research and development to payment and insurance [3]